SparingVision Revenue and Competitors
Estimated Revenue & Valuation
- SparingVision's estimated annual revenue is currently $4M per year.
- SparingVision's estimated revenue per employee is $77,500
Employee Data
- SparingVision has 52 Employees.
- SparingVision grew their employee count by 4% last year.
SparingVision's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Development Sciences Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | COO | Reveal Email/Phone |
6 | CFO | Reveal Email/Phone |
7 | VP Corporate Development | Reveal Email/Phone |
8 | SVP, Regulatory Affairs & Quality Assurance at SparingVision | Reveal Email/Phone |
9 | Associate Director Nonclinical Operations | Reveal Email/Phone |
10 | Director Development Sciences | Reveal Email/Phone |
SparingVision Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4M | 52 | 4% | N/A | N/A |
What Is SparingVision?
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
keywords:N/A
N/A
Total Funding
52
Number of Employees
$4M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Paris
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.5M | 52 | 30% | N/A |
#2 | $7.5M | 52 | -33% | N/A |
#3 | $4.8M | 52 | 4% | N/A |
#4 | $6.8M | 52 | 53% | N/A |
#5 | $11.4M | 52 | 6% | N/A |